NASDAQ: GLUE
Monte Rosa Therapeutics Inc Stock Ownership - Who owns Monte Rosa Therapeutics?

Insider buying vs selling

Have Monte Rosa Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Edmund DunnPrincipal Accounting Officer2025-06-032,062$4.45
$9.17kSell
Chandra P. LeoDirector2025-03-2410,000$5.84
$58.38kBuy
Versant Venture Capital VI LP10% Owner2024-10-2915,600$9.41
$146.80kSell
Versant Venture Capital VI LP10% Owner2024-10-2952,305$9.08
$475.03kSell
Versant Venture Capital VI LP10% Owner2024-10-2889,990$9.66
$869.21kSell
Versant Venture Capital VI LP10% Owner2024-09-201,132,566$6.53
$7.40MSell

1 of 1

GLUE insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when GLUE insiders and whales buy or sell their stock.

GLUE Shareholders

What type of owners hold Monte Rosa Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Bradley J. Phd Bolzon14.46%8,897,053$57.56MInsider
Versant Venture Capital VI LP12.60%7,750,860$50.15MInsider
Mohamad Makhzoumi12.51%7,692,298$49.77MInsider
Joshua Makower12.51%7,692,298$49.77MInsider
Edward T. Mathers12.51%7,692,298$49.77MInsider
New Enterprise Associates 17 LP12.51%7,692,298$49.77MInsider
Scott D. Sandell12.51%7,692,298$49.77MInsider
Peter W. Sonsini12.51%7,692,298$49.77MInsider
Paul Edward Walker12.51%7,692,298$49.77MInsider
Rick Yang12.51%7,692,298$49.77MInsider

1 of 3

GLUE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
GLUE34.03%65.97%Net Selling
FULC62.17%37.83%Net Selling
LXRX21.70%78.30%Net Selling
OCGN17.67%10.44%Net Selling
INBX71.67%28.33%Net Buying

Monte Rosa Therapeutics Stock Ownership FAQ

Who owns Monte Rosa Therapeutics?

Monte Rosa Therapeutics (NASDAQ: GLUE) is owned by 101.12% institutional shareholders, 196.06% Monte Rosa Therapeutics insiders, and 0.00% retail investors. Bradley J. Phd Bolzon is the largest individual Monte Rosa Therapeutics shareholder, owning 8.90M shares representing 14.46% of the company. Bradley J. Phd Bolzon's Monte Rosa Therapeutics shares are currently valued at $56.59M.

If you're new to stock investing, here's how to buy Monte Rosa Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.